Taipei, Taiwan, June 26, 2024 – MYCENAX (TWO:4726) and Chitose Laboratory Corp., a leading Japanese cell line development company, have signed an agreement to jointly initiate a new chapter in the scale-up production and marketing activities for the host super cell line, Supercell. This collaboration has successfully transferred the high-yield production clones and processes developed by CHITOSE, utilizing their revolutionary Supercell host, CHO-MK cells*). Currently, the high-yield production process (5-10g/L) has been successfully reproduced at Mycenax. We plan to scale up the bioreactor process to 50L this year, laying the foundation for future commercial-scale expansion and manufacturing services.

This collaboration represents the agreement between MYCENAX and CHITOSE to accelerate the development of biopharmaceuticals and reduce manufacturing costs. This partnership aims to further shorten the timeline for the development and commercialization of innovative drugs and biosimilars for the biologics developers, making significant contributions to the global healthcare industry.

As a leading company in the global platform for cell line development, CHITOSE has been dedicated to developing innovative technologies that inject new energy into the global bioeconomy. CHITOSE exclusive Supercell CHO cell line establishment is regarded as a milestone breakthrough in the field, offering fresh possibilities for the development and production of biopharmaceuticals.

As the BEST PARTNER in Contract Development and Manufacturing Organization (CDMO), MYCENAX offers comprehensive services for the development and manufacturing of both traditional and emerging biopharmaceuticals. By bridging upstream and downstream industries, we provide end-to-end services for development and manufacturing, accelerating the production process of biopharmaceuticals, reducing manufacturing costs, and providing global biopharmaceutical developers with innovative and efficient bioprocessing solutions and high-quality biopharmaceutical products.

We look forward to continuing our collaboration to accelerate efficiency in the field of biopharmaceuticals and make even greater contributions to human health and well-being.

(CHITOSE's Chief Technology Officer, Takayuki Horiuchi, Ph.D., delivered a public lecture titled " Empowering Bio-manufacturing with Supercells and Processes​" at Japan BioPharma EXPO 2024.)

*) The establishment of CHO-MK cells was supported by AMED under the Grant Number JP18ae0101054.